Business Context and Reporting Period
This Form 8-K is filed by Landec Corporation (not Lifecore Biomedical, Inc.) on August 24, 2020, reporting events occurring on August 25, 2020. The filing serves as a Regulation FD disclosure regarding a material corporate transaction.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on the announcement of a definitive agreement to sell a specific asset.
Material Changes
- Asset Sale: The Company entered into a definitive agreement to sell its manufacturing facility located in Hanover, Pennsylvania, along with related assets.
- Disclosure Method: The details were communicated via a press release issued on August 25, 2020, which is attached as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the transaction itself. The press release incorporated by reference is not deemed "filed" for purposes of Section 18 of the Exchange Act, limiting the legal liability of the specific details within the press release text.
Investor Verification Checklist
- Verify the final sale price and terms of the Hanover, Pennsylvania facility in the attached press release (Exhibit 99.1).
- Confirm the expected closing date of the asset sale.
- Assess the impact of this divestiture on the Company's future manufacturing capacity and operational footprint.
- Note that the registrant name in the filing is Landec Corporation (LNDC), not Lifecore Biomedical, Inc.